310 MONOGRAPHS / EL + EN

Monograph library

Find the exact preparation and read its basis, references and final decision.

Ingredient, name or codeDosage formOrigin

Use scopeWith arithmetic scaling

310 monographs

CGR-BP-001 · 10.0

Aqueous Calamine Cream

Reference monograph · Local adoption

Cream

Reference scalingRead →

CGR-BP-002 · 10.0

Aqueous Cream

Reference monograph · Local adoption

Cream

Reference readingRead →

CGR-BP-003 · 10.0

Benzyl Benzoate Application

Reference monograph · Local adoption

Emulsion

Reference readingRead →

CGR-BP-004 · 10.0

Buffered Cream

Reference monograph · Local adoption

Cream

Reference readingRead →

CGR-BP-005 · 10.0

Calamine and Coal Tar Ointment

Reference monograph · Local adoption

Ointment

Reference scalingRead →

CGR-BP-006 · 10.0

Calamine Lotion

Reference monograph · Local adoption

Cutaneous suspension

Reference scalingRead →

CGR-BP-007 · 10.0

Calamine Ointment

Reference monograph · Local adoption

Ointment

Reference scalingRead →

CGR-BP-008 · 10.0

Calcium Hydroxide Solution

Reference monograph · Local adoption

Liquid base or auxiliary solution

Reference scalingRead →

CGR-BP-009 · 10.0

Cetomacrogol Emulsifying Ointment

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-BP-010 · 10.0

Cetomacrogol Emulsifying Wax

Reference monograph · Local adoption

Emulsifying wax

Reference scalingRead →

CGR-BP-011 · 10.0

Cetrimide Cream 0.5% w/w

Reference monograph · Local adoption

Cream

Reference scalingRead →

CGR-BP-012 · 10.0

Compound Zinc Paste

Reference monograph · Local adoption

Paste

Reference scalingRead →

CGR-BP-013 · 10.0

Dithranol Ointment

Reference monograph · Local adoption

Ointment

Reference readingRead →

CGR-BP-014 · 10.0

Emulsifying Ointment

Reference monograph · Local adoption

Semi-solid base

Reference readingRead →

CGR-BP-015 · 10.0

Emulsifying Wax

Purchased-material specification

Emulsifying wax

Reference readingRead →

CGR-BP-016 · 10.0

Glycerol Suppositories

Reference monograph · Local adoption

Suppositories

Reference scalingRead →

CGR-BP-017 · 10.0

Hydrous Ointment

Reference monograph · Local adoption

Cream

Reference scalingRead →

CGR-BP-018 · 10.0

Magnesium Sulfate Paste

Reference monograph · Local adoption

Paste

Reference readingRead →

CGR-BP-019 · 10.0

Methyl Salicylate Ointment

Reference monograph · Local adoption

Ointment

Reference scalingRead →

CGR-BP-020 · 10.0

Simple Ointment

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-BP-021 · 10.0

Sodium Bicarbonate Ear Drops

Reference monograph · Local adoption

Ear solution or drops

Reference scalingRead →

CGR-BP-022 · 10.0

Syrup

Reference monograph · Local adoption

Oral vehicle

Reference scalingRead →

CGR-BP-023 · 10.0

Wool Alcohols Ointment

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-BP-024 · 10.0

Zinc and Castor Oil Ointment

Reference monograph · Local adoption

Ointment

Reference scalingRead →

CGR-BP-025 · 10.0

Zinc and Coal Tar Paste

Reference monograph · Local adoption

Paste

Reference readingRead →

CGR-BP-026 · 10.0

Zinc and Ichthammol Cream

Reference monograph · Local adoption

Cream

Reference scalingRead →

CGR-BP-027 · 10.0

Zinc and Salicylic Acid Paste

Reference monograph · Local adoption

Paste

Reference scalingRead →

CGR-BP-028 · 10.0

Zinc Cream

Reference monograph · Local adoption

Cream

Reference scalingRead →

CGR-BP-029 · 10.0

Zinc Ointment

Reference monograph · Local adoption

Ointment

Reference scalingRead →

CGR-BP-030 · 10.0

Alcoholic Iodine Solution

Reference monograph · Local adoption

Cutaneous solution

Reference scalingRead →

CGR-BP-031 · 10.0

Aqueous Iodine Oral Solution

Reference monograph · Local adoption

Oral solution

Reference scalingRead →

CGR-BP-032 · 10.0

Aluminium Acetate Ear Drops

Reference monograph · Local adoption

Ear solution or drops

Reference readingRead →

CGR-BP-033 · 10.0

Flexible Collodion

Specialist setting only

Cutaneous solution

Reference readingRead →

CGR-BP-034 · 10.0

Benzoin Inhalation

Reference monograph · Local adoption

Inhalation-vapour solution

Reference scalingRead →

CGR-BP-035 · 10.0

Compound Benzoin Tincture

Reference monograph · Local adoption

Tincture

Reference scalingRead →

CGR-BP-036 · 10.0

Peppermint Spirit

Reference monograph · Local adoption

Liquid base or auxiliary solution

Reference scalingRead →

CGR-BE-001 · 10.0

Diluent A FTM — lactose

Reference monograph · Local adoption

Powder excipient

Reference scalingRead →

CGR-BE-002 · 10.0

Diluent B FTM — mannitol

Reference monograph · Local adoption

Powder excipient

Reference scalingRead →

CGR-BE-003 · 10.0

Preserved water FTM

Reference monograph · Local adoption

Liquid base or auxiliary solution

Reference scalingRead →

CGR-BE-004 · 10.0

Buffered cetomacrogol cream FTM

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-BE-005 · 10.0

Carbomer 980 gel FTM

Reference monograph · Local adoption

Gel base

Reference scalingRead →

CGR-BE-006 · 10.0

Hydrated sorbitan sesquioleate petrolatum FTM

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-BE-007 · 10.0

MCC/carmellose dispersion FTM

Reference monograph · Local adoption

Liquid base or auxiliary solution

Reference scalingRead →

CGR-BE-008 · 10.0

Permethrin cream 5% w/w FTM

Reference monograph · Local adoption

Cream

Reference scalingRead →

CGR-BE-009 · 10.0

Hydrocortisone acetate cream 1% FTM

Reference monograph · Local adoption

Cream

Reference scalingRead →

CGR-BE-010 · 10.0

Urea lipophilic cream 10% FTM

Reference monograph · Local adoption

Cream

Reference readingRead →

CGR-BE-011 · 10.0

Urea hydrophilic cream 10% FTM

Reference monograph · Local adoption

Cream

Reference scalingRead →

CGR-BE-012 · 10.0

Metronidazole gel 1% FTM

Reference monograph · Local adoption

Cutaneous gel

Reference scalingRead →

CGR-BE-013 · 10.0

Minoxidil cutaneous solution 2% w/w FTM

Reference monograph · Local adoption

Cutaneous solution

Reference scalingRead →

CGR-BE-014 · 10.0

Spironolactone capsules 25 mg FTM

Reference monograph · Local adoption

Hard capsules

Reference scalingRead →

CGR-BE-015 · 10.0

Omeprazole oral suspension 2 mg/g FTM

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-BE-016 · 10.0

Paracetamol capsules 250–500 mg FTM

Reference monograph · Local adoption

Hard capsules

Reference readingRead →

CGR-BE-017 · 10.0

Macrocrystalline nitrofurantoin oral suspension 6 mg/mL FTM

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-BE-018 · 10.0

Trimethoprim oral suspension 10 mg/mL FTM

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-BE-019 · 10.0

Riboflavin capsules 400 mg FTM

Reference monograph · Local adoption

Hard capsules

Reference scalingRead →

CGR-BE-020 · 10.0

Miconazole base oral gel 2% FTM

Reference monograph · Local adoption

Oral gel

Reference readingRead →

CGR-FR-001 · 10.0

Iodine alcoholic solution 1% Ph. Fr.

Reference monograph · Local adoption

Cutaneous solution

Reference scalingRead →

CGR-FR-002 · 10.0

Cosmetic cerate Ph. Fr.

Reference monograph · Local adoption

Cream

Reference scalingRead →

CGR-FR-003 · 10.0

Galen cerate Ph. Fr.

Reference monograph · Local adoption

Cream

Reference scalingRead →

CGR-FR-004 · 10.0

Modified Galen cerate Ph. Fr.

Reference monograph · Local adoption

Cream

Reference scalingRead →

CGR-FR-005 · 10.0

Glycerinated cerate Ph. Fr.

Reference monograph · Local adoption

Cream

Reference scalingRead →

CGR-FR-006 · 10.0

Collodion Ph. Fr.

Final reference document

Liquid base or auxiliary solution

Reference readingRead →

CGR-FR-007 · 10.0

Therapeutic placebo tablets Ph. Fr.

Reference monograph · Local adoption

Tablets

Reference scalingRead →

CGR-FR-008 · 10.0

Oleo-calcareous cream Ph. Fr.

Final reference document

Cream

Reference readingRead →

CGR-FR-009 · 10.0

Carmine capsules 200–500 mg Ph. Fr.

Reference monograph · Local adoption

Hard capsules

Reference readingRead →

CGR-FR-010 · 10.0

Nadolol capsules 1–50 mg Ph. Fr.

Reference monograph · Local adoption

Hard capsules

Reference readingRead →

CGR-FR-011 · 10.0

Starch glycerolate Ph. Fr.

Reference monograph · Local adoption

Gel base

Reference scalingRead →

CGR-FR-012 · 10.0

Zinc oxide starch glycerolate Ph. Fr.

Reference monograph · Local adoption

Paste

Reference scalingRead →

CGR-FR-013 · 10.0

Therapeutic placebo capsules Ph. Fr.

Reference monograph · Local adoption

Hard capsules

Reference readingRead →

CGR-FR-014 · 10.0

Spironolactone capsules 0.5–25 mg Ph. Fr.

Reference monograph · Local adoption

Hard capsules

Reference readingRead →

CGR-FR-015 · 10.0

Sodium chloride capsules 50 mg–1 g Ph. Fr.

Reference monograph · Local adoption

Hard capsules

Reference readingRead →

CGR-FR-016 · 10.0

Amiodarone hydrochloride capsules 5–200 mg Ph. Fr.

Reference monograph · Local adoption

Hard capsules

Reference readingRead →

CGR-FR-017 · 10.0

Sodium bicarbonate capsules Ph. Fr.

Reference monograph · Local adoption

Hard capsules

Reference readingRead →

CGR-FR-018 · 10.0

Oleo-calcareous liniment Ph. Fr.

Reference monograph · Local adoption

Emulsion

Reference scalingRead →

CGR-FR-019 · 10.0

Salicylic acid ointment 1–50% Ph. Fr.

Reference monograph · Local adoption

Ointment

Reference readingRead →

CGR-FR-020 · 10.0

Zinc oxide paste, Lassar, Ph. Fr.

Reference monograph · Local adoption

Paste

Reference scalingRead →

CGR-FR-021 · 10.0

Acacia oral vehicle (potion gommeuse) Ph. Fr.

Reference monograph · Local adoption

Oral vehicle

Reference scalingRead →

CGR-FR-022 · 10.0

Copper and zinc ointment, camphor-free Dalibour

Reference monograph · Local adoption

Ointment

Reference scalingRead →

CGR-FR-023 · 10.0

Camphor ointment 10% or 20% Ph. Fr.

Reference monograph · Local adoption

Ointment

Reference readingRead →

CGR-FR-024 · 10.0

Zinc oxide ointment 10% Ph. Fr.

Reference monograph · Local adoption

Ointment

Reference scalingRead →

CGR-FR-025 · 10.0

Aqueous zinc paste, Darier, Ph. Fr.

Reference monograph · Local adoption

Paste

Reference scalingRead →

CGR-FR-026 · 10.0

Therapeutic placebo syrup Ph. Fr.

Reference monograph · Local adoption

Oral syrup

Reference readingRead →

CGR-FR-027 · 10.0

Simple syrup Ph. Fr.

Reference monograph · Local adoption

Oral vehicle

Reference scalingRead →

CGR-FR-028 · 10.0

Glycerol oral solution 0.644 g/mL Ph. Fr.

Reference monograph · Local adoption

Oral solution

Reference scalingRead →

CGR-ES-001 · 10.0

Beeler cream base AEMPS

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-ES-002 · 10.0

Preserved water without propylene glycol AEMPS

Reference monograph · Local adoption

Liquid base or auxiliary solution

Reference scalingRead →

CGR-ES-003 · 10.0

AEMPS preserved syrup — nominal 84% w/v

Reference monograph · Local adoption

Oral vehicle

Reference scalingRead →

CGR-ES-004 · 10.0

Sodium carmellose oral gel 1% AEMPS

Reference monograph · Local adoption

Oral vehicle

Reference scalingRead →

CGR-ES-005 · 10.0

Metronidazole gel 1% AEMPS

Reference monograph · Local adoption

Cutaneous gel

Reference scalingRead →

CGR-ES-006 · 10.0

Hydrochlorothiazide oral suspension 2 mg/mL AEMPS

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-ES-007 · 10.0

Captopril oral solution 1 mg/mL AEMPS

Reference monograph · Local adoption

Oral solution

Reference scalingRead →

CGR-ES-008 · 10.0

Furosemide oral solution 2 mg/mL AEMPS

Reference monograph · Local adoption

Oral solution

Reference scalingRead →

CGR-ES-009 · 10.0

Enalapril maleate oral solution 1 mg/mL AEMPS

Reference monograph · Local adoption

Oral solution

Reference scalingRead →

CGR-ES-010 · 10.0

Amlodipine 0.5 mg/mL oral solution

Reference monograph · Local adoption

Oral solution

Reference scalingRead →

CGR-ES-011 · 10.0

Hydrocortisone oral suspension 1 mg/mL AEMPS

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-ES-012 · 10.0

Gabapentin oral solution 50 mg/mL AEMPS

Reference monograph · Local adoption

Oral solution

Reference scalingRead →

CGR-ES-013 · 10.0

Sodium citrate/citric acid oral solution AEMPS

Reference monograph · Local adoption

Oral solution

Reference scalingRead →

CGR-ES-014 · 10.0

Artificial saliva AEMPS

Reference monograph · Local adoption

Oromucosal preparation

Reference scalingRead →

CGR-ES-015 · 10.0

Urea cream 15% AEMPS

Final reference document

Cream

Reference readingRead →

CGR-ES-016 · 10.0

Minoxidil cutaneous solution 2% w/w AEMPS

Reference monograph · Local adoption

Cutaneous solution

Reference scalingRead →

CGR-BP-037 · 10.0

Cetrimide Emulsifying Ointment

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-BP-038 · 10.0

Chloroxylenol Solution

Reference monograph · Local adoption

Cutaneous solution

Reference scalingRead →

CGR-BP-039 · 10.0

Coal Tar Solution

Reference monograph · Local adoption

Liquid base or auxiliary solution

Reference scalingRead →

CGR-BP-040 · 10.0

Strong Coal Tar Solution

Reference monograph · Local adoption

Liquid base or auxiliary solution

Reference scalingRead →

CGR-BP-041 · 10.0

Compound Benzoic Acid Ointment

Reference monograph · Local adoption

Ointment

Reference readingRead →

CGR-BP-042 · 10.0

Compound Aluminium Paste

Reference monograph · Local adoption

Paste

Reference scalingRead →

CGR-BP-043 · 10.0

Compound Glucose Sodium Chloride and Sodium Citrate Oral Solution

Reference monograph · Local adoption

Oral solution

Reference scalingRead →

CGR-BP-044 · 10.0

Soap Spirit

Reference monograph · Local adoption

Liquid base or auxiliary solution

Reference scalingRead →

CGR-BP-045 · 10.0

Concentrated Anise Water

Reference monograph · Local adoption

Liquid base or auxiliary solution

Reference readingRead →

CGR-BP-046 · 10.0

Concentrated Camphor Water

Reference monograph · Local adoption

Liquid base or auxiliary solution

Reference scalingRead →

CGR-BP-047 · 10.0

Concentrated Cinnamon Water

Reference monograph · Local adoption

Liquid base or auxiliary solution

Reference readingRead →

CGR-BP-048 · 10.0

Benzoic Acid Solution

Reference monograph · Local adoption

Liquid base or auxiliary solution

Reference scalingRead →

CGR-BE-021 · 10.0

Buffered Cetomacrogol Emulsion FTM

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-BE-022 · 10.0

Anionic Hydrophilic Cream FTM

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-BE-023 · 10.0

Econazole Nitrate Cream 1% w/w

Reference monograph · Local adoption

Cream

Reference scalingRead →

CGR-BE-024 · 10.0

Miconazole Nitrate Cream 2% w/w

Reference monograph · Local adoption

Cream

Reference scalingRead →

CGR-BE-025 · 10.0

Miconazole Nitrate Emulsion 2% w/w

Reference monograph · Local adoption

Emulsion

Reference scalingRead →

CGR-BE-026 · 10.0

Crotamiton Cream 10% w/w

Reference monograph · Local adoption

Cream

Reference scalingRead →

CGR-BE-027 · 10.0

Crotamiton Emulsion 10% w/w

Reference monograph · Local adoption

Emulsion

Reference readingRead →

CGR-BE-028 · 10.0

Clindamycin Phosphate Solution 1.5% w/w as Clindamycin

Reference monograph · Local adoption

Cutaneous solution

Reference scalingRead →

CGR-BE-029 · 10.0

Erythromycin Gel 2% or 4% w/w

Reference monograph · Local adoption

Cutaneous gel

Reference readingRead →

CGR-BE-030 · 10.0

Erythromycin Hydroalcoholic Solution 4% w/w

Reference monograph · Local adoption

Cutaneous solution

Reference scalingRead →

CGR-BE-031 · 10.0

Acetazolamide Capsules 250 mg

Reference monograph · Local adoption

Hard capsules

Reference scalingRead →

CGR-BE-032 · 10.0

Hydrocortisone Capsules 10 or 20 mg

Reference monograph · Local adoption

Hard capsules

Reference readingRead →

CGR-BE-033 · 10.0

Cetirizine Dihydrochloride Capsules 10 mg

Reference monograph · Local adoption

Hard capsules

Reference scalingRead →

CGR-BE-034 · 10.0

Diosmin Capsules 500 mg

Reference monograph · Local adoption

Hard capsules

Reference scalingRead →

CGR-BE-035 · 10.0

Loperamide Hydrochloride Capsules 2 mg

Reference monograph · Local adoption

Hard capsules

Reference scalingRead →

CGR-BE-036 · 10.0

Aciclovir Oral Suspension 400 mg/5 mL

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-BE-037 · 10.0

Metronidazole Benzoate Suspension 200 mg/5 mL as Metronidazole

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-BE-038 · 10.0

Ibuprofen Gel 5% w/w

Reference monograph · Local adoption

Cutaneous gel

Reference scalingRead →

CGR-BE-039 · 10.0

Aluminium Chloride Hexahydrate Solution 15% w/w

Reference monograph · Local adoption

Cutaneous solution

Reference scalingRead →

CGR-BE-040 · 10.0

Hydrogen Peroxide Ear Solution 3% w/w

Reference monograph · Local adoption

Ear solution or drops

Reference scalingRead →

CGR-ES-017 · 10.0

Hydroxybenzoate Concentrate EX025

Reference monograph · Local adoption

Liquid base or auxiliary solution

Reference scalingRead →

CGR-ES-018 · 10.0

Preserved Water EX001

Reference monograph · Local adoption

Liquid base or auxiliary solution

Reference scalingRead →

CGR-ES-019 · 10.0

Nonionic O/W Emulsion 1 EX010

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-ES-020 · 10.0

Nonionic O/W Emulsion 2 EX011

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-ES-021 · 10.0

Neutral Carbomer 940 Gel EX020

Reference monograph · Local adoption

Gel base

Reference scalingRead →

CGR-ES-022 · 10.0

Simple Syrup 84% w/v EX022

Reference monograph · Local adoption

Oral vehicle

Reference scalingRead →

CGR-ES-023 · 10.0

Aluminium Acetate Solution AEMPS

Reference monograph · Local adoption

Ear solution or drops

Reference readingRead →

CGR-ES-024 · 10.0

Acetic Acid Ear Drops AEMPS

Reference monograph · Local adoption

Ear solution or drops

Reference scalingRead →

CGR-ES-025 · 10.0

Lidocaine Hydrochloride Anaesthetic Gel 1% w/w

Reference monograph · Local adoption

Cutaneous gel

Reference scalingRead →

CGR-ES-026 · 10.0

Hydrocortisone Cream 0.5% w/w AEMPS

Reference monograph · Local adoption

Cream

Reference scalingRead →

CGR-ES-027 · 10.0

Viscous Lidocaine Hydrochloride 0.5% w/w

Reference monograph · Local adoption

Oromucosal preparation

Reference scalingRead →

CGR-ES-028 · 10.0

Weak Lugol Solution AEMPS 2025

Reference monograph · Local adoption

Oral solution

Reference scalingRead →

CGR-ES-029 · 10.0

Clonidine Hydrochloride Oral Solution 20 micrograms/mL

Reference monograph · Local adoption

Oral solution

Reference scalingRead →

CGR-ES-030 · 10.0

Isoniazid Oral Solution 50 mg/mL

Reference monograph · Local adoption

Oral solution

Reference scalingRead →

CGR-ES-031 · 10.0

Ethambutol Hydrochloride Oral Solution 50 mg/mL

Reference monograph · Local adoption

Oral solution

Reference scalingRead →

CGR-ES-032 · 10.0

Pyridoxine Hydrochloride Oral Solution 25 mg/mL

Reference monograph · Local adoption

Oral solution

Reference scalingRead →

CGR-ES-033 · 10.0

Dexamethasone Oral Solution 1 mg/mL

Reference monograph · Local adoption

Oral solution

Reference readingRead →

CGR-ES-034 · 10.0

Hydralazine Hydrochloride Oral Solution 10 mg/mL

Reference monograph · Local adoption

Oral solution

Reference scalingRead →

CGR-ES-035 · 10.0

Folic Acid Oral Solution 1 mg/mL

Reference monograph · Local adoption

Oral solution

Reference scalingRead →

CGR-ES-036 · 10.0

Thiamine Hydrochloride Oral Solution 100 mg/mL

Reference monograph · Local adoption

Oral solution

Reference scalingRead →

CGR-ES-037 · 10.0

Riboflavin Oral Solution 25 mg/mL

Reference monograph · Local adoption

Oral solution

Reference scalingRead →

CGR-ES-038 · 10.0

Aqueous Chlorhexidine Digluconate Solution 0.1% AEMPS

Reference monograph · Local adoption

Cutaneous solution

Reference scalingRead →

CGR-ES-039 · 10.0

Disodium Eosin Aqueous Solution 2% w/v

Reference monograph · Local adoption

Cutaneous solution

Reference scalingRead →

CGR-ES-040 · 10.0

Zinc Sulfate Heptahydrate Solution 0.1% w/v

Reference monograph · Local adoption

Cutaneous solution

Reference scalingRead →

CGR-JP-001 · 10.0

Absorptive Cream JP

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-JP-002 · 10.0

Hydrophilic Cream JP

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-JP-003 · 10.0

Macrogol Ointment JP

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-JP-004 · 10.0

Hydrophilic Petrolatum JP

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-US-001 · 10.0

Acetazolamide 25 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-US-002 · 10.0

Allopurinol 20 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-US-003 · 10.0

Amiodarone 5 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-US-004 · 10.0

Atenolol 2 mg/mL oral solution

Reference monograph · Local adoption

Oral solution

Reference scalingRead →

CGR-US-005 · 10.0

Bethanechol 5 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-US-006 · 10.0

Carvedilol 0.5 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-US-007 · 10.0

Celecoxib 10 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-US-008 · 10.0

Cinacalcet 5 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-US-009 · 10.0

Lamotrigine 1 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-US-010 · 10.0

Nifedipine 4 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-US-011 · 10.0

Quinidine sulfate 10 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-US-012 · 10.0

Rifabutin 20 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-US-013 · 10.0

Tinidazole 66.7 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-US-014 · 10.0

Verapamil 50 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-CA-001 · 10.0

Baclofen 10 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-CA-002 · 10.0

Clobazam 1 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-CA-003 · 10.0

Diazoxide 10 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-CA-004 · 10.0

Domperidone 1 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-CA-005 · 10.0

Glycopyrrolate 0.5 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-CA-006 · 10.0

Lisinopril 1 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-CA-007 · 10.0

Prednisone 5 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-NZ-001 · 10.0

Melatonin 1 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-NZ-002 · 10.0

Carvedilol 1 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-NZ-003 · 10.0

Sotalol hydrochloride 5 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-NZ-004 · 10.0

Terbinafine 25 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-NZ-005 · 10.0

Dipyridamole 10 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-NZ-006 · 10.0

Flecainide acetate 20 mg/mL oral suspension

Reference monograph · Local adoption

Oral suspension

Reference scalingRead →

CGR-NZ-007 · 10.0

Phenobarbital sodium 10 mg/mL oral solution

Reference monograph · Local adoption

Oral solution

Reference scalingRead →

CGR-BR-001 · 10.0

Paraben concentrate 6% + 3% w/w

Reference monograph · Local adoption

Liquid base or auxiliary solution

Reference scalingRead →

CGR-BR-002 · 10.0

Citric acid 25–50% w/v auxiliary solution

Fresh intermediate · Same operation

Liquid base or auxiliary solution

Reference readingRead →

CGR-BR-003 · 10.0

Imidazolidinyl urea 50% w/v preservative solution

Fresh intermediate · Same operation

Liquid base or auxiliary solution

Reference scalingRead →

CGR-BR-004 · 10.0

Triethanolamine 50% w/v auxiliary solution

Fresh intermediate · Same operation

Liquid base or auxiliary solution

Reference scalingRead →

CGR-BR-005 · 10.0

High-viscosity hydroxyethylcellulose gel

Reference monograph · Local adoption

Gel base

Reference scalingRead →

CGR-BR-006 · 10.0

Fluid hydroxyethylcellulose gel

Reference monograph · Local adoption

Gel base

Reference scalingRead →

CGR-BR-007 · 10.0

Nonionic lotion base I — FNFB

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-BR-008 · 10.0

Vanishing cream — FNFB

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-BR-009 · 10.0

Anionic cream I — FNFB

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-BR-010 · 10.0

Sodium chloride 25% w/v thickening intermediate

Fresh intermediate · Same operation

Liquid base or auxiliary solution

Reference scalingRead →

CGR-BR-011 · 10.0

Sodium fluoride 0.05% w/v mouth rinse

Reference monograph · Local adoption

Oromucosal preparation

Reference scalingRead →

CGR-BR-012 · 10.0

Chlorhexidine digluconate 0.1% w/v mouth rinse

Reference monograph · Local adoption

Oromucosal preparation

Reference scalingRead →

CGR-BR-013 · 10.0

Aluminium hydroxide 6% w/v suspension

Final reference document

Oral suspension

Reference readingRead →

CGR-BR-014 · 10.0

Aluminium hydroxide 6% and magnesium hydroxide 4% w/v suspension

Final reference document

Oral suspension

Reference readingRead →

CGR-BR-015 · 10.0

Lidocaine hydrochloride 2% w/v oromucosal topical solution

Reference monograph · Local adoption

Oromucosal preparation

Reference scalingRead →

CGR-BR-016 · 10.0

Simple syrup 85% w/v — FNFB

Fresh intermediate · Same operation

Oral vehicle

Reference scalingRead →

CGR-FR-029 · 10.0

Amoxicillin 125 / 250 / 500 mg capsules from bulk API

Reference monograph · Local adoption

Hard capsules

Reference readingRead →

CGR-FR-030 · 10.0

Aprepitant 20 mg/mL from 80 mg capsules

Reference monograph · Local adoption

Oral suspension

Reference readingRead →

CGR-FR-031 · 10.0

Clarithromycin 250 / 500 mg capsules

Reference monograph · Local adoption

Hard capsules

Reference readingRead →

CGR-FR-032 · 10.0

Flucytosine 50 mg/mL oral suspension

Specialist setting only

Oral suspension

Reference readingRead →

CGR-FR-033 · 10.0

Sertraline 25 / 50 mg capsules

Reference monograph · Local adoption

Hard capsules

Reference readingRead →

CGR-FR-034 · 10.0

Quetiapine 50 / 100 / 150 mg immediate-release capsules

Reference monograph · Local adoption

Hard capsules

Reference readingRead →

CGR-ES-041 · 10.0

Firm hydrophilic cream 1 EX003

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-ES-042 · 10.0

Firm hydrophilic cream 2 EX004

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-ES-043 · 10.0

Anionic O/W emulsion EX007

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-ES-044 · 10.0

Fluid nonionic O/W emulsion EX009

Reference monograph · Local adoption

Emulsion

Reference scalingRead →

CGR-ES-045 · 10.0

Nonionic O/W emulsion 3 EX012

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-ES-046 · 10.0

W/O emulsion EX005 Cold cream

Reference monograph · Local adoption

Semi-solid base

Reference scalingRead →

CGR-ES-047 · 10.0

Water-in-silicone emulsion EX006

Final reference document

Semi-solid base

Reference readingRead →

CGR-ES-048 · 10.0

Fluid anionic O/W emulsion EX008

Reference monograph · Local adoption

Emulsion

Reference scalingRead →

CGR-ES-049 · 10.0

Capsule diluent 1 EX013

Reference monograph · Local adoption

Powder excipient

Reference scalingRead →

CGR-ES-050 · 10.0

Capsule diluent 2 EX014

Reference monograph · Local adoption

Powder excipient

Reference scalingRead →

CGR-ES-051 · 10.0

Oral adhesive gel EX015

Reference monograph · Local adoption

Gel base

Reference scalingRead →

CGR-ES-052 · 10.0

Carmellose sodium gel 2% EX016

Reference monograph · Local adoption

Gel base

Reference scalingRead →

CGR-ES-053 · 10.0

Methylcellulose gel 4% EX017

Reference monograph · Local adoption

Gel base

Reference scalingRead →

CGR-ES-054 · 10.0

Fluid methylcellulose gel 1% EX018

Reference monograph · Local adoption

Gel base

Reference scalingRead →

CGR-ES-055 · 10.0

Hydroalcoholic methylcellulose gel EX019

Reference monograph · Local adoption

Gel base

Reference scalingRead →

CGR-ES-056 · 10.0

Neutral hydroalcoholic carbomer gel EX021

Reference monograph · Local adoption

Gel base

Reference scalingRead →

CGR-ES-057 · 10.0

Bentonite magma 5% EX023

Reference monograph · Local adoption

Gel base

Reference scalingRead →

CGR-ES-058 · 10.0

Hydroalcoholic vehicle 1 EX026

Reference monograph · Local adoption

Liquid base or auxiliary solution

Reference readingRead →

CGR-ES-059 · 10.0

Hydroalcoholic vehicle 2 EX027

Reference monograph · Local adoption

Liquid base or auxiliary solution

Reference readingRead →

CGR-ES-060 · 10.0

Camphorated oil 10% PO001

Reference monograph · Local adoption

Cutaneous solution

Reference scalingRead →

CGR-ES-061 · 10.0

Salicylic oil 5% with ethanol PO003

Reference monograph · Local adoption

Cutaneous solution

Reference scalingRead →

CGR-ES-062 · 10.0

Salicylic oil 5% without ethanol PO004

Reference monograph · Local adoption

Cutaneous solution

Reference scalingRead →

CGR-ES-063 · 10.0

Thymol water 0.1% PO008

Reference monograph · Local adoption

Oromucosal preparation

Reference scalingRead →

CGR-ES-064 · 10.0

Menthol spirit 5% w/v PO012

Reference monograph · Local adoption

Cutaneous solution

Reference scalingRead →

CGR-ES-065 · 10.0

Calamine lotion PO014

Reference monograph · Local adoption

Cutaneous suspension

Reference scalingRead →

CGR-ES-066 · 10.0

Aqueous zinc paste PO017

Reference monograph · Local adoption

Paste

Reference scalingRead →

CGR-ES-067 · 10.0

Lassar paste without salicylic acid PO018

Reference monograph · Local adoption

Paste

Reference scalingRead →

CGR-ES-068 · 10.0

Mentholated zinc oxide powder PO020

Reference monograph · Local adoption

Cutaneous powder

Reference scalingRead →

CGR-ES-069 · 10.0

Menthol petrolatum 1% PO031

Reference monograph · Local adoption

Ointment

Reference scalingRead →

CGR-ES-070 · 10.0

Hydrocortisone acetate 0.5%, phenol 0.5%, menthol 0.2% and zinc oxide 2% cream

Reference monograph · Local adoption

Cream, O/W emulsion

Reference scalingRead →

CGR-ES-071 · 10.0

Salicylic acid 5% and triamcinolone acetonide 0.1% cream

Reference monograph · Local adoption

Cream, O/W emulsion

Reference scalingRead →

CGR-ES-072 · 10.0

Silver nitrate cutaneous solution 2% w/w

Reference monograph · Local adoption

Solution for external pharmaceutical use

Reference scalingRead →

CGR-ES-073 · 10.0

Tannic acid alcoholic solution 10% w/v

Reference monograph · Local adoption

Solution for external pharmaceutical use

Reference scalingRead →

CGR-ES-074 · 10.0

Menthol 10% and methyl salicylate 15% analgesic ointment

Reference monograph · Local adoption

Cutaneous ointment / ointment base

Reference scalingRead →

CGR-ES-075 · 10.0

Copper sulfate pentahydrate cutaneous solution 0.1% w/v

Reference monograph · Local adoption

Solution for external pharmaceutical use

Reference scalingRead →

CGR-ES-076 · 10.0

Rosemary essential oil alcoholic solution 5% v/v

Reference monograph · Local adoption

Solution for external pharmaceutical use

Reference scalingRead →

CGR-ES-077 · 10.0

Peru balsam ointment 6% w/w

Reference monograph · Local adoption

Cutaneous ointment / ointment base

Reference scalingRead →

CGR-ES-078 · 10.0

Camphor spirit 10% w/v

Reference monograph · Local adoption

Solution for external pharmaceutical use

Reference scalingRead →

CGR-ES-079 · 10.0

Menthol 1% and thymol 1% rubefacient in rosemary spirit

Reference monograph · Local adoption

Solution for external pharmaceutical use

Reference scalingRead →

CGR-JP-005 · 10.0

White Ointment JP

Reference monograph · Local adoption

Cutaneous ointment / ointment base

Reference scalingRead →

CGR-JP-006 · 10.0

Zinc Oxide Ointment JP 20% w/w

Reference monograph · Local adoption

Cutaneous ointment / ointment base

Reference scalingRead →

CGR-JP-007 · 10.0

Ethanol for Disinfection JP

Reference monograph · Local adoption

Solution for external pharmaceutical use

Reference scalingRead →

CGR-JP-008 · 10.0

Iodine Tincture JP 6% with potassium iodide 4%

Reference monograph · Local adoption

Solution for external pharmaceutical use

Reference scalingRead →

CGR-JP-009 · 10.0

Zinc Oxide Starch Powder JP 50% w/w

Reference monograph · Local adoption

Cutaneous powder

Reference scalingRead →

CGR-JP-010 · 10.0

Sulfur and Camphor Lotion JP

Reference monograph · Local adoption

Cutaneous suspension / lotion

Reference readingRead →

CGR-JP-011 · 10.0

Salicylic Acid Spirit JP 3% w/v

Reference monograph · Local adoption

Cutaneous alcoholic solution

Reference scalingRead →

CGR-JP-012 · 10.0

Salicylated Alum Powder JP 3% w/w

Reference monograph · Local adoption

Cutaneous powder

Reference scalingRead →

CGR-JP-013 · 10.0

Hydrocortisone Acetate 0.5% and Diphenhydramine Base 0.5% Ointment JP

Reference monograph · Local adoption

Cutaneous ointment

Reference scalingRead →

CGR-JP-014 · 10.0

Acrinol Hydrate 1% and Zinc Oxide Ointment JP

Reference monograph · Local adoption

Cutaneous ointment

Reference scalingRead →

CGR-JP-015 · 10.0

Zinc Oxide Oil JP 50% w/w — Olive Oil JP variant

Reference monograph · Local adoption

Oily cutaneous suspension

Reference scalingRead →

CGR-JP-016 · 10.0

Acrinol Hydrate 1% and Zinc Oxide Oil JP

Reference monograph · Local adoption

Oily cutaneous suspension

Reference scalingRead →

CGR-FR-035 · 10.0

Patent Blue V coloured alcohol 60% v/v

Reference document · Local adoption required

Cutaneous hydroalcoholic solution

Reference readingRead →

CGR-FR-036 · 10.0

Silver nitrate sticks 633 mg/g

Reference document · Local adoption required

Solid cutaneous sticks

Reference readingRead →

CGR-FR-037 · 10.0

Colloidal silver ointment

Reference document · Local adoption required

Hydrophobic ointment for cutaneous use

Reference readingRead →

CGR-FR-038 · 10.0

Hawthorn tincture

Reference document · Local adoption required

Herbal tincture

Reference readingRead →

CGR-FR-039 · 10.0

Witch-hazel tincture

Reference document · Local adoption required

Herbal tincture

Reference readingRead →

CGR-FR-040 · 10.0

Hawthorn fluid extract

Reference document · Local adoption required

Herbal fluid extract

Reference readingRead →

CGR-FR-041 · 10.0

Witch-hazel fluid extract

Reference document · Local adoption required

Herbal fluid extract

Reference readingRead →

CGR-FR-042 · 10.0

Passionflower fluid extract

Reference document · Local adoption required

Herbal fluid extract

Reference readingRead →

CGR-ES-080 · 10.0

Salicylic acid 6% and triamcinolone acetonide 0.1% gel

Reference document · Local adoption required

Cutaneous gel

Reference readingRead →

CGR-ES-081 · 10.0

Salicylic acid and lactic acid collodion

Reference document · Local adoption required

Film-forming cutaneous liquid

Reference readingRead →

CGR-ES-082 · 10.0

Erythromycin 2% cream

Reference document · Local adoption required

Oil-in-water cream for cutaneous use

Reference readingRead →

CGR-ES-083 · 10.0

Methadone hydrochloride 10 mg/mL (1% w/v) aqueous oral solution

Reference document · Local adoption required

Oral solution

Reference readingRead →

CGR-ES-084 · 10.0

Morphine hydrochloride 10 mg/mL (1% w/v) oral solution with simple syrup

Reference document · Local adoption required

Oral solution

Reference readingRead →

CGR-ES-085 · 10.0

Lidocaine HCl 1% compound buccal suspension

Reference document · Local adoption required

Buccal/oropharyngeal suspension

Reference readingRead →

CGR-ES-086 · 10.0

Phenobarbital 10 mg/mL expressed as base, from sodium salt — oral solution

Reference document · Local adoption required

Oral solution

Reference readingRead →

CGR-ES-087 · 10.0

Chloral hydrate 5% w/v enema (50 mg/mL)

Reference document · Local adoption required

Viscous aqueous solution for rectal administration

Reference readingRead →

CGR-ES-088 · 10.0

Chloral hydrate 10% w/v oral syrup with preservative (100 mg/mL)

Reference document · Local adoption required

Oral syrup, solution

Reference readingRead →

CGR-ES-089 · 10.0

Gomenol 2% w/w cutaneous oil solution

Reference document · Local adoption required

Cutaneous oil solution

Reference readingRead →

CGR-ES-090 · 10.0

Tannic acid cutaneous solution in ethanol–glycerol, 5 g/50 mL/50 mL formula

Reference document · Local adoption required

Alcoholic–glycerol cutaneous solution

Reference readingRead →

CGR-ES-091 · 10.0

Boric acid 3% w/v aqueous cutaneous solution

Reference document · Local adoption required

Aqueous cutaneous solution

Reference readingRead →

CGR-ES-092 · 10.0

Saturated boric acid otic solution in ethanol 70% — 5 g/100 mL charge

Reference document · Local adoption required

Alcoholic otic solution

Reference readingRead →

CGR-ES-093 · 10.0

Iodine 2% w/v alcoholic solution with potassium iodide 2.5% w/v

Reference document · Local adoption required

Alcoholic cutaneous solution

Reference readingRead →

CGR-ES-094 · 10.0

Glycerol–wheat starch cutaneous gel, 90/10/10 g formula

Reference document · Local adoption required

Cutaneous gel

Reference readingRead →

CGR-ES-095 · 10.0

Potassium permanganate 0.01% w/v (1 in 10,000) cutaneous solution

Reference document · Local adoption required

Aqueous cutaneous solution

Reference readingRead →

CGR-ES-096 · 10.0

Racemic camphor 10% w/w ointment with white beeswax 8% w/w

Reference document · Local adoption required

Hydrophobic cutaneous ointment

Reference readingRead →

CGR-ES-097 · 10.0

Povidone-iodine 10% w/v in buffered vehicle, cutaneous solution

Reference document · Local adoption required

Cutaneous solution

Reference readingRead →

CGR-ES-098 · 10.0

Borax 1% w/v mouth-rinse solution

Reference document · Local adoption required

Oromucosal solution, not for swallowing

Reference readingRead →

CGR-ES-099 · 10.0

Racemic menthol 1% w/w in talc

Reference document · Local adoption required

Cutaneous powder

Reference readingRead →

CGR-ES-100 · 10.0

Boric acid 10% w/w in white soft paraffin

Reference document · Local adoption required

Oleaginous cutaneous ointment

Reference readingRead →

CGR-ES-101 · 10.0

Salicylic acid 5% w/w ointment with 3% liquid paraffin

Reference document · Local adoption required

Ointment

Reference readingRead →

CGR-ES-102 · 10.0

Alibour water with copper sulfate 0.1%, zinc sulfate 0.4% and camphor 0.1% w/v

Reference document · Local adoption required

Cutaneous solution

Reference readingRead →

CGR-ES-103 · 10.0

Glycerinated alcohol —50 g glycerol plus 50 mL hydroalcoholic vehicle 2

Reference document · Local adoption required

Cutaneous hydroalcoholic solution

Reference readingRead →

CGR-ES-104 · 10.0

Methyl salicylate 1%, menthol 3% and camphor 2.5% w/w analgesic cream

Reference document · Local adoption required

Oil-in-water cream

Reference readingRead →

CGR-ES-105 · 10.0

Boric acid/tannic acid foot powder with thymol

Reference document · Local adoption required

Cutaneous powder for soles

Reference readingRead →

CGR-ES-106 · 10.0

Barbados aloes dried leaf juice 50 mg — hard capsules

Reference document · Local adoption required

Hard capsules for oral use

Reference readingRead →

CGR-ES-107 · 10.0

Cascara bark 300 mg — hard capsules

Reference document · Local adoption required

Hard capsules for oral use

Reference readingRead →

CGR-ES-108 · 10.0

Frangula bark 300 mg — hard capsules

Reference document · Local adoption required

Hard capsules for oral use

Reference readingRead →

CGR-ES-109 · 10.0

Ispaghula husk with fructose/maltodextrin — powder for oral suspension

Reference document · Local adoption required

Powder for oral suspension prepared immediately before administration

Reference readingRead →

CGR-ES-110 · 10.0

Standardised frangula bark dry extract 50 mg — hard capsules

Reference document · Local adoption required

Hard capsules for oral use

Reference readingRead →

CGR-ES-111 · 10.0

Standardised senna leaf dry extract 100 mg — hard capsules

Reference document · Local adoption required

Hard capsules for oral use

Reference readingRead →

CGR-ES-112 · 10.0

Fennel fruit 250 mg — hard capsules

Reference document · Local adoption required

Hard capsules for oral use

Reference readingRead →

CGR-ES-113 · 10.0

Bearberry leaf 400 mg — herbal powder hard capsules

Reference document · Local adoption required

Hard capsules for oral use

Reference readingRead →

CGR-ES-114 · 10.0

Orthosiphon leaf 400 mg — herbal powder hard capsules

Reference document · Local adoption required

Hard capsules for oral use

Reference readingRead →

CGR-ES-115 · 10.0

Rosemary leaf 250 mg — herbal powder hard capsules

Reference document · Local adoption required

Hard capsules for oral use

Reference readingRead →

CGR-ES-116 · 10.0

Senna leaf 300 mg — hard capsules

Reference document · Local adoption required

Hard capsules for oral use

Reference readingRead →

CGR-ES-117 · 10.0

Garlic bulb powder 500 mg — herbal powder hard capsules

Reference document · Local adoption required

Hard capsules for oral use

Reference readingRead →

CGR-ES-118 · 10.0

Devil’s claw root 500 mg — herbal powder hard capsules

Reference document · Local adoption required

Hard capsules for oral use

Reference readingRead →

CGR-ES-119 · 10.0

Valerian root 500 mg — herbal powder hard capsules

Reference document · Local adoption required

Hard capsules for oral use

Reference readingRead →

CGR-ES-120 · 10.0

Psyllium seed powder with fructose/maltodextrin — powder for oral suspension

Reference document · Local adoption required

Powder for oral suspension prepared immediately before administration

Reference readingRead →